Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters











Publication year range
1.
Chem Pharm Bull (Tokyo) ; 67(11): 1211-1224, 2019.
Article in English | MEDLINE | ID: mdl-31685749

ABSTRACT

A novel series of 2,6,7-substituted 3-unsubstituted 1,2,3,4-tetrahydroisoquinoline derivatives were synthesized to find a peroxisome proliferator-activated receptor γ (PPARγ) partial agonist. Among the derivatives, (E)-7-[2-(cyclopent-3-eny)-5-methyloxazol-4-ylmethoxy]-2-[3-(2-furyl)acryloyl]-6-(1H-tetrazol-5-yl)-1,2,3,4-tetrahydroisoquinoline (20g) exhibited potent partial agonist activity (EC50 = 13 nM, maximal response 30%) and very weak protein tyrosine phosphatase 1B (PTP1B) inhibition (IC50 = 1100 nM), indicating a selective PPARγ partial agonist. A computational docking calculation revealed that 20g bound to PPARγ in a similar manner to that of known partial agonists. In male and female KK-Ay mice with insulin resistance and hyperglycemia, 20g at 30 mg/kg for 7 d significantly reduced plasma glucose levels, but not triglyceride levels. The effects of 20g were similar to those of pioglitazone at 10 mg/kg. In conclusion, the 2,6,7-substituted 1,2,3,4-tetrahydroisoquinoline with an acidic group at the 6-position provides a novel scaffold for selective PPARγ partial agonists and 20g exerted anti-diabetic effects via the partial activation of PPARγ.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Hyperglycemia/drug therapy , Hypoglycemic Agents/pharmacology , PPAR gamma/agonists , Tetrahydroisoquinolines/pharmacology , Administration, Oral , Animals , Blood Glucose/drug effects , Crystallography, X-Ray , Female , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/chemistry , Insulin Resistance , Male , Mice , Mice, Transgenic , Molecular Docking Simulation , Molecular Structure , Rats , Rats, Sprague-Dawley , Tetrahydroisoquinolines/administration & dosage , Tetrahydroisoquinolines/chemistry
3.
Bioorg Med Chem ; 20(2): 1060-75, 2012 Jan 15.
Article in English | MEDLINE | ID: mdl-22197396

ABSTRACT

A novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and (S)-2-[(2E,4E)-hexadienoyl]-7-(2-{5-methyl-2-[(1E)-5-methylhexen-1-yl]oxazol-4-yl}ethoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (14i) was identified as a potent human peroxisome proliferator-activated receptor γ (PPARγ) selective agonist (EC(50)=0.03 µM) and human protein-tyrosine phosphatase 1B (PTP-1B) inhibitor (IC(50)=1.18 µM). C(max) after oral administration of 14i at 10mg/kg was 2.2 µg/ml (4.5 µM) in male SD rats. Repeated administration of 14i and rosiglitazone for 14 days dose-dependently decreased plasma glucose levels, ED(50)=4.3 and 23 mg/kg/day, respectively, in male KK-A(y) mice. In female SD rats, repeated administration of 14i at 12.5-100mg/kg/day for 28 days had no effect on the hematocrit value (Ht) and red blood cell count (RBC), while rosiglitazone significantly decreased them from 25mg/kg/day. In conclusion, 14i showed about a fivefold stronger hypoglycemic effect and fourfold or more weaker hemodilution effect than rosiglitazone, indicating that 14i is 20-fold or more safer than rosiglitazone. Compound 14i is a promising candidate for an efficacious and safe anti-diabetic drug targeting PPARγ and PTP-1B.


Subject(s)
Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Isoquinolines/chemistry , Isoquinolines/pharmacology , Oxazoles/chemistry , Oxazoles/pharmacology , PPAR gamma/agonists , Protein Tyrosine Phosphatase, Non-Receptor Type 1/antagonists & inhibitors , Administration, Oral , Animals , Enzyme Activation/drug effects , Female , Humans , Hypoglycemic Agents/chemical synthesis , Isoquinolines/chemical synthesis , Male , Mice , Oxazoles/chemical synthesis , PPAR gamma/metabolism , Protein Tyrosine Phosphatase, Non-Receptor Type 1/metabolism , Rats , Rats, Sprague-Dawley , Stereoisomerism , Structure-Activity Relationship , Tetrahydroisoquinolines/chemical synthesis , Tetrahydroisoquinolines/chemistry , Tetrahydroisoquinolines/pharmacology
4.
Chem Pharm Bull (Tokyo) ; 59(10): 1233-42, 2011.
Article in English | MEDLINE | ID: mdl-21963632

ABSTRACT

Novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and (S)-7-(2-{2-[(E)-2-cyclopentylvinyl]-5-methyloxazol-4-yl}ethoxy)-2-[(2E,4E)-hexadienoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (14c) was identified as a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist. The transactivation activity of 14c was comparable to that of rosiglitazone in human PPARγ (EC50=0.14 µM) and was much higher than in human PPARα (EC50=0.20 µM). In addition, 14c, but not rosiglitazone, showed human protein-tyrosine phosphatase 1B (PTP-1B) inhibitory activity (IC50=1.85 µM). 14c showed about 10-fold stronger hypoglycemic and hypotriglyceridemic effects than rosiglitazone by repeated application for 14 d in male KK-Ay mice. Furthermore, 14c, but not rosiglitazone, increased hepatic peroxisome acyl CoA oxidase activity at 30 mg/kg/d for 7 d in male Syrian hamsters, probably due to its PPARα agonist activity. 14c did not affect plasma volume at 100 mg/kg/d for 14 d in male ICR mice, while rosiglitazone significantly increased it. In conclusion, 14c is a promising candidate for an efficacious and safe anti-diabetic drug with triple actions as a PPARα/γ dual agonist with PTP-1B inhibitory activity.


Subject(s)
Enzyme Inhibitors/pharmacology , Hypoglycemic Agents/pharmacology , Peroxisome Proliferator-Activated Receptors/agonists , Protein Tyrosine Phosphatases/antagonists & inhibitors , Quinazolinones/pharmacology , Tetrahydroisoquinolines/pharmacology , Animals , Blood Glucose/drug effects , Carboxylic Acids/chemistry , Cricetinae , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Evaluation, Preclinical , Enzyme Inhibitors/adverse effects , Enzyme Inhibitors/chemistry , Humans , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/chemistry , Male , Mice , Mice, Inbred ICR , Molecular Targeted Therapy , Quinazolinones/chemical synthesis , Quinazolinones/chemistry , Rosiglitazone , Tetrahydroisoquinolines/adverse effects , Tetrahydroisoquinolines/chemical synthesis , Tetrahydroisoquinolines/chemistry , Thiazolidinediones/pharmacology
5.
Chem Pharm Bull (Tokyo) ; 58(8): 1057-65, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20686260

ABSTRACT

To find a novel acyl-CoA: cholesterol acyltransferase inhibitor, a series of sulfamide derivatives were synthesized and evaluated. Compound 1d, in which carboxymethyl moiety at the 5-position of Pactimibe was replaced by a sulfamoylamino group, showed 150-fold more potent anti-foam cell formation activity (IC(50): 0.02 microM), 1.6-fold higher log D(7.0) (4.63), and a slightly lower protein binding ratio (93.2%) than Pactimibe. Compound 1i, in which the octyl chain at the 1-position in 1d was replaced by an ethoxyethyl, showed markedly low log D(7.0) (1.73) and maintained 3-fold higher anti-foam cell formation activity (IC(50): 1.0 microM), than Pactimibe. The plasma protein binding ratio (PBR) of 1i was much lower than that of Pactimibe (62.5% vs. 98.1%), and its partition ratio to the rabbit atherosclerotic aorta after oral administration was higher than that of Pactimibe. Compound 1i at 10 microM markedly inhibited cholesterol esterification in atherosclerotic rabbit aortas even when incubated with serum, while Pactimibe had little effect probably due to its high PBR. In conclusion, compound 1i is expected to more efficiently inhibit the progression of atherosclerosis than Pactimibe.


Subject(s)
Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Indoles/pharmacology , Sterol O-Acyltransferase/antagonists & inhibitors , Sulfonamides/chemistry , Sulfonamides/pharmacology , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Cholesterol/metabolism , Enzyme Inhibitors/chemical synthesis , Esterification , Hydrophobic and Hydrophilic Interactions , Indoles/chemical synthesis , Indoles/chemistry , Male , Molecular Structure , Protein Binding , Rabbits , Solubility , Stereoisomerism , Structure-Activity Relationship , Sulfonamides/chemical synthesis
6.
Chem Pharm Bull (Tokyo) ; 58(8): 1066-76, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20686261

ABSTRACT

To find a novel acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor with anti-lipid peroxidative activity, a series of tetrahydroisoquinoline derivatives were synthesized and evaluated. A compound with a N-(4-hydroxy-2,3,5-trimethylphenyl)carbamoyl moiety at the 3-position and an octanoyl moiety at the 2-position (7) was demonstrated to show anti-foam cell formation activity stronger than and anti-lipid peroxidative activity comparable to those of Pactimibe, while it was hardly absorbed orally. To increase its bioavailability, the acyl chain at the 2-position was shortened and various polar or basic moieties were introduced at the 7-position of 7. Among the synthesized derivatives, (S)-7-dimethylamino-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-isobutyryl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide hydrochloride (21) showed about 16-fold stronger anti-foam cell formation activity, 3-fold stronger hepatic ACAT inhibitory activity, similar anti-low density lipoprotein (LDL) oxidative activity and 2-fold more potent protective activity against macrophage cell death by oxidative stress in comparison with Pactimibe. Compound 21 was efficiently absorbed after oral administration at 10 mg/kg in rats and dogs and its C(max) values were higher than its IC(50) values for in vitro activities. In conclusion, a tetrahydroisoquinoline structure is a useful scaffold for designing a phenolic anti-oxidative ACAT inhibitor, and compound 21 is expected to effectively prevent atherosclerosis.


Subject(s)
Antioxidants/pharmacology , Enzyme Inhibitors/pharmacology , Lipid Peroxidation/drug effects , Sterol O-Acyltransferase/antagonists & inhibitors , Tetrahydroisoquinolines/pharmacology , Animals , Antioxidants/chemical synthesis , Antioxidants/chemistry , Cell Death/drug effects , Cholesterol/metabolism , Dogs , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Esterification , Macrophages/drug effects , Macrophages/metabolism , Male , Molecular Structure , Oxidative Stress/drug effects , Rabbits , Rats , Rats, Sprague-Dawley , Stereoisomerism , Structure-Activity Relationship , Tetrahydroisoquinolines/chemical synthesis , Tetrahydroisoquinolines/chemistry
7.
Arzneimittelforschung ; 60(6): 315-9, 2010.
Article in English | MEDLINE | ID: mdl-20648920

ABSTRACT

Isolated rat mesenteric arteries were incubated with lipopolysaccharide (LPS) for 6 h and then mounted in an organ bath to investigate their responses to various relaxants. Exposure to LPS moderately reduced acetylcholine (ACh)-induced endothelium-dependent relaxation (EDR), and markedly reduced sodium nitroprusside (SNP)-induced endothelium-independent relaxation (EIR). It did not affect ACh-induced EDR under treatment with a nitric oxide synthase (NOS) inhibitor, which is mediated by an endothelium-derived hyperpolarizing factor (EDHF), and forskolin-induced EIR. N-(3-(Aminomethyl)benzyl)acetamidine (1400 W), an inducible nitric oxide synthase (iNOS) inhibitor, actinomycin D, an RNA polymerase inhibitor, cycloheximide, a protein synthesis inhibitor, and dexamethazone reduced the nitric oxide (NO) production and reversed the reduced ACh-induced EDR and SNP-induced EIR. In LPS-treated mesenteric artery, L-arginine-induced relaxation was not affected by removal of endothelium, indicating muscular inducible nitric oxide synthase (iNOS) induction. Pre-exposure to SNP (NO donor) also moderately reduced ACh-induced EDR and markedly reduced SNP-induced EIR with little effect on ACh-induced EDHF-mediated EDR. In conclusion, in vitro exposure to LPS desensitized vascular smooth muscle cells to endogenous and exogenous NO by overproduction of muscular iNOS-derived NO, and an iNOS inhibitor and iNOS induction inhibitors prevented the LPS-induced desensitization.


Subject(s)
Amidines/pharmacology , Benzylamines/pharmacology , Dexamethasone/pharmacology , Enzyme Inhibitors/pharmacology , Lipopolysaccharides/pharmacology , Mesenteric Arteries/physiology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide/pharmacology , Vasodilation/physiology , Animals , Cycloheximide/pharmacology , Dactinomycin/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Male , Mesenteric Arteries/drug effects , Nitric Oxide/antagonists & inhibitors , Nitroprusside/pharmacology , Rats , Rats, Sprague-Dawley , Vasodilation/drug effects , Vasodilator Agents/pharmacology
8.
Vascul Pharmacol ; 51(2-3): 147-53, 2009.
Article in English | MEDLINE | ID: mdl-19539781

ABSTRACT

In rabbit intrapulmonary arteries, substance P (SP) has been reported to induce endothelium-dependent relaxation (EDR) and endothelium-dependent contraction (EDC) via tachykinin NK(1) receptors, and endothelium-independent contraction (EIC) via tachykinin NK(2) receptors. The present study pharmacologically examined whether these opposite responses (EDR and EDC) are mediated by the same NK(1) receptor. Five tachykinin agonists, including septide, a reportedly atypical NK(1) agonist, caused concentration-dependent EDR in the presence of NK2 antagonist (SR-48968) + TXA2 synthetase inhibitor (ozagrel), which blocked EIC and EDC, in pre-contracted arteries, and concentration-dependent EDC in the presence of NK2 antagonist (SR-48968) + nitric oxide synthase inhibitor (l-N(G)-nitro-arginine methyl ester), which blocked EIC and EDR, in non-contracted arteries. The EC(50) values of these agonists for EDR were smaller than those for EDC, indicating that the affinities of NK(1) agonists to NK(1) receptors are different between EDR and EDC. However, the rank order of their potency for EDR and EDC was the same: SP = septide > SP methyl ester (SPME) > neurokinin A > neurokinin B. [Ala(5), beta-Ala(8)]-alpha-neurokinin fragment 4-10 (NK2 agonist) and senktide (NK3 agonist) caused no responses. Two structurally different NK(1) antagonists, CP-99994 and SR-140333, shifted the concentration-EDC and -EDR curves of SPME, a selective NK(1) agonist, and septide rightward and suppressed their maximal responses in a similar concentration-dependent manner, indicating that the affinities of NK(1) antagonists to NK1 receptors are similar between EDR and EDC. U-73122, a phospholipase C inhibitor, and thapsigargin, 2,5-di-tert-butylhydroquinone, and ruthenium red, all intracellular Ca2+ release blockers, inhibited SP-induced EDR and EDC. Effective concentrations of ionomycin (Ca2+ ionophore) causing EDR were also lower than those causing EDC. Taken together, SP-induced EDR and EDC are mediated by activation of the same NK1 receptor followed by an increase in intracellular Ca2+, and sensitivity to Ca2+ may be higher in the EDR than EDC pathway.


Subject(s)
Calcium Signaling/physiology , Endothelium, Vascular/physiology , Pulmonary Artery/physiology , Receptors, Neurokinin-1/physiology , Vasoconstriction/physiology , Vasodilation/physiology , Animals , Calcium Channel Blockers/pharmacology , Inhibitory Concentration 50 , Ionophores , Male , Neurokinin A/metabolism , Neurokinin A/pharmacology , Neurokinin B/metabolism , Neurokinin B/pharmacology , Neurokinin-1 Receptor Antagonists , Nitric Oxide Synthase/antagonists & inhibitors , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Phosphoinositide Phospholipase C/antagonists & inhibitors , Pyrrolidonecarboxylic Acid/analogs & derivatives , Pyrrolidonecarboxylic Acid/metabolism , Pyrrolidonecarboxylic Acid/pharmacology , Rabbits , Receptors, Neurokinin-1/agonists , Receptors, Neurokinin-2/agonists , Receptors, Neurokinin-2/antagonists & inhibitors , Receptors, Neurokinin-3/agonists , Substance P/analogs & derivatives , Substance P/metabolism , Substance P/pharmacology , Thromboxane-A Synthase/antagonists & inhibitors
9.
Life Sci ; 83(23-24): 810-4, 2008 Dec 05.
Article in English | MEDLINE | ID: mdl-18952112

ABSTRACT

AIMS: The present study examined whether substance P (SP)-induced endothelium-dependent TXA(2)-mediated contraction (EDC), nitric oxide (NO)-mediated relaxation (EDR), and endothelium-independent contraction (EIC) are different between the rabbit proximal and distal intrapulmonary arteries. MAIN METHODS: The helically cut strips of isolated proximal and distal arteries were fixed vertically between hooks in organ bath, and changes in isometric tension were measured. KEY FINDINGS: SP-induced EDC was greater in the distal than proximal arteries, and EDR was greater in the proximal than distal arteries. However, under the complete blockade of NK(2) receptors and NO production, SP (10(-9)-3x10(-7) M)-induced EDC did not differ between proximal and distal arteries. Under the complete blockade of NK(2) receptors and TXA(2) production, SP (3x10(-10)-3x10(-8) M)-induced EDR was greater in the proximal than distal arteries. Neither contraction induced by U-46619, a TXA(2) agonist, nor relaxation by sodium nitroprusside, an NO donor, was different between both portions of the arteries. Both ionomycin (10(-8) M)- and l-arginine (1 mM)-induced EDRs were also significantly greater in the proximal than distal arteries. Under the blockade of NK(1) receptors and NO and TXA(2) production, SP (10(-7) M)-induced EIC was greater in the distal than proximal arteries. In summary, the capacity for NO production is higher in the proximal than distal arteries, resulting in SP-induced higher EDR and lower EDC in the proximal arteries. SIGNIFICANCE: These regional differences in responses to SP may play important roles in maintaining the homogenous distribution of blood flow in the lung.


Subject(s)
Endothelium, Vascular/drug effects , Pulmonary Artery/drug effects , Substance P/pharmacology , Vasoconstriction/drug effects , Vasodilation/drug effects , Animals , Endothelium, Vascular/physiology , In Vitro Techniques , Male , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/physiology , Nitric Oxide/metabolism , Nitric Oxide Donors/pharmacology , Pulmonary Artery/metabolism , Pulmonary Artery/physiology , Rabbits , Receptors, Neurokinin-2/metabolism , Thromboxane A2/agonists , Thromboxane A2/biosynthesis , Vasoconstriction/physiology , Vasoconstrictor Agents/pharmacology , Vasodilation/physiology
10.
Chem Pharm Bull (Tokyo) ; 56(3): 335-45, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18310946

ABSTRACT

A novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and biologically evaluated. (S)-2-Benzyl-7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (10, KY-021) was identified as a novel peroxisome proliferators-activated receptor (PPAR) gamma agonist, which showed potent activity in human PPAR gamma (EC50=11.8 nM). KY-021 reduced plasma glucose and triglyceride levels at 3 mg/kg/d for 7 d in male KK-Ay mice. KY-021 also decreased plasma triglyceride levels at 0.3-3 mg/kg/d for 6 d, and improved oral glucose tolerance at 1 and 3 mg/kg/d for 7 d in male Zucker fatty rats. Maximal plasma concentration of KY-021 after oral administration at 10 mg/kg was 6.6 microg/ml and 2.1 microg/ml in male ICR mice and male SD rats, respectively. Repeated oral administration of KY-021 at 30 mg/kg/d for 10 weeks had little toxicity in male SD rats. These results demonstrated that KY-021 has great potential as an efficacious and safe drug for diabetes.


Subject(s)
PPAR gamma/agonists , Tetrahydroisoquinolines/pharmacology , 3T3 Cells , Adipocytes/drug effects , Animals , Blood Glucose/metabolism , Cell Differentiation/drug effects , Chemical Phenomena , Chemistry, Physical , Chromatography, Thin Layer , Cyclization , Hypoglycemic Agents/chemical synthesis , Hypoglycemic Agents/pharmacology , Hypolipidemic Agents/chemical synthesis , Hypolipidemic Agents/pharmacology , Indicators and Reagents , Magnetic Resonance Spectroscopy , Mass Spectrometry , Mice , Mice, Inbred ICR , Oxazoles/blood , Oxazoles/pharmacokinetics , Rats , Rats, Sprague-Dawley , Rats, Zucker , Spectrophotometry, Infrared , Structure-Activity Relationship , Triglycerides/blood , Tyrosine/analogs & derivatives , Tyrosine/blood , Tyrosine/pharmacokinetics
11.
Naunyn Schmiedebergs Arch Pharmacol ; 377(4-6): 401-10, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18228001

ABSTRACT

Diabetes is a risk factor of ischemic heart disease, cerebral ischemia, and atherosclerosis, in which endothelial dysfunction plays a role in the pathogenesis. We examined vascular responses in the aorta of pre-diabetic db/db mice with normoglycemia, hyperlipidemia, and hyperinsulinemia (6 weeks old), and diabetic db/db mice with hyperglycemia, hyperlipidemia, and hyperinsulinemia (11 weeks old) in comparison with age-matched non-diabetic db/+ mice. Prostaglandin F2alpha (PGF2alpha)-induced contraction was significantly enhanced in the aorta of diabetic but not pre-diabetic db/db mice compared to age-matched non-diabetic db/+ mice. Acetylcholine (ACh), adenosine-5'-diphosphate (ADP), NaF, a G protein activator and A-23187, a Ca-ionophore, caused endothelium-dependent and nitric oxide (NO)-mediated relaxation, and sodium nitroprusside (SNP), an NO donor, caused endothelium-independent relaxation in the pre-contracted aorta of db/db mice. Maximal endothelium-dependent ACh-induced relaxation was reduced in diabetic but not pre-diabetic db/db mice compared to age-matched db/+ mice, while maximal SNP-induced relaxation was not different between diabetic and non-diabetic mice. ACh-induced relaxation in diabetic db/db mice was not affected by ozagrel, a thromboxane A2 (TXA2) synthetase inhibitor, or acetylsalicylic acid (aspirin), a cyclooxygenase inhibitor, suggesting no involvement of endogenous TXA2 or prostanoids in the reduction of relaxation. Maximal endothelium-dependent ADP-, A-23187-, and NaF-induced relaxation was not reduced in diabetic db/db mice. EC50 values for ACh- and SNP-induced relaxation were increased in diabetic but not pre-diabetic db/db mice, suggesting decreases in sensitivity to NO in diabetic mice. Two-week treatment with KV-5070, a PPARgamma agonist, lowered plasma glucose, triglyceride (TG), and insulin but not cholesterol, and reversed the reduced ACh-induced relaxation. In conclusion, ACh-induced endothelium-dependent relaxation is impaired in diabetic db/db mice, probably due to the dysfunction of ACh receptors and/or receptor-G protein coupling. Endothelial dysfunction was not genetic and was considered to be initiated primarily by hyperglycemia, and was improved by anti-diabetic treatment with a PPARgamma agonist.


Subject(s)
Acetylcholine/pharmacology , Diabetes Mellitus, Type 2/physiopathology , Endothelium, Vascular/metabolism , Vasodilator Agents/pharmacology , Animals , Aorta, Thoracic/physiopathology , Diabetes Mellitus, Experimental/physiopathology , Hyperglycemia/physiopathology , Hyperinsulinism/physiopathology , Hyperlipidemias/physiopathology , Male , Mice , Nitric Oxide/metabolism , PPAR gamma/agonists , Receptors, Cholinergic/drug effects , Receptors, Cholinergic/metabolism , Receptors, G-Protein-Coupled/metabolism , Tetrahydroisoquinolines/pharmacology
12.
Life Sci ; 82(1-2): 79-84, 2008 Jan 02.
Article in English | MEDLINE | ID: mdl-18037448

ABSTRACT

THP-1 cell-derived foam cells were exposed to oxidative stress through combined treatment with acetylated LDL (acLDL) and copper ions (Cu2+). The foam cells showed caspase-dependent apoptotic changes on exposure to oxidative stress for 6 h, and necrotic changes with the leakage of LDH after 24 h. KY-455, an anti-oxidative ACAT inhibitor, and ascorbic acid (VC) but not YM-750, an ACAT inhibitor, prevented apoptotic and necrotic changes. These preventive effects of KY-455 and VC were accompanied by the inhibition of lipid peroxidation in culture medium containing acLDL and Cu2+, suggesting the involvement of oxidized acLDL in apoptosis and necrosis. Foam cells accumulated esterified cholesterol (EC) for 24 h in the presence of acLDL without Cu2+, which was suppressed by KY-455 and YM-750. Foam cells showed necrotic changes and died in the presence of acLDL and Cu2+. KY-455 but not YM-750 prevented cell death and reduced the amount of EC accumulated. The foam cells treated with VC further accumulated EC without necrotic changes for 24 h even in the presence of acLDL and Cu2+. YM-750 as well as KY-455 inhibited lipid accumulation when co-incubated with VC in foam cells exposed to oxidative stress. It is concluded that an anti-oxidative ACAT inhibitor or the combination of an antioxidant and an ACAT inhibitor protects foam cells from oxidative stress and effectively reduces cholesterol levels, which would be a promising approach in anti-atherosclerotic therapy.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/drug effects , Cholesterol/metabolism , Foam Cells/drug effects , Indoles/pharmacology , Oxidative Stress/drug effects , Propane/analogs & derivatives , Sterol O-Acyltransferase/antagonists & inhibitors , Animals , Ascorbic Acid/pharmacology , Cell Line , Copper Sulfate/pharmacology , Foam Cells/metabolism , Foam Cells/pathology , Lipid Peroxidation/drug effects , Lipoproteins, LDL/pharmacology , Necrosis , Propane/pharmacology , Rabbits , Thiobarbituric Acid Reactive Substances/metabolism
13.
Arzneimittelforschung ; 58(12): 666-72, 2008.
Article in English | MEDLINE | ID: mdl-19202739

ABSTRACT

A novel series of 1-alkyl-7-amido-indoline-based anti-oxidative acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors have been reported and are expected to lower plasma cholesterol levels due to the inhibition of intestinal and hepatic ACAT, and to inhibit cholesterol accumulation in macrophages due to the inhibition of low density lipoprotein (LDL) oxidation. In the present study, relationships between lipophilicity and biological activities were examined in 13 derivatives. Lipophilicity (logP) increased and water solubility decreased with dependence on the number of carbons in the 1-alkyl chain. Inhibitory activity against both in vitro intestinal ACAT and LDL oxidation positively correlated with logP; however, the optimum logP, at which the level of activity is maximal, differed between these two effects. Inhibitory activity against in vitro plasma oxidation was weakly dependent on logP. Plasma concentrations of the derivatives after oral administration at 10 mg/kg correlated negatively with logP and positively with water solubility. Hypocholesterolemic activity in rats fed a high-cholesterol diet, and the ratio of Cmax and IC50 values for ACAT inhibition, an index of effective plasma concentration, positively and highly correlated with logP, while ex vivo inhibitory activity against plasma oxidation in rats, and the ratio of Cmax and IC50 values for the inhibition of plasma oxidation negatively correlated with logP. In conclusion, in vitro ACAT inhibitory and anti-oxidative activity were differently dependent on logP, and intestinal absorption was inversely dependent on lipophilicity in indoline-based anti-oxidative ACAT inhibitors. The hypocholesterolemic effect positively correlated and the ex vivo anti-oxidative effect negatively correlated with lipophilicity. Optimum logP as a bioavailable dual inhibitor against in vivo ACAT and lipid peroxidation was estimated to be 3.8 (1-pentyl and 1-isopentyl derivatives) in the present series of derivatives.


Subject(s)
Anticholesteremic Agents/chemical synthesis , Anticholesteremic Agents/pharmacology , Antioxidants/chemical synthesis , Antioxidants/pharmacology , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Indoles/chemical synthesis , Indoles/pharmacology , Sterol O-Acyltransferase/antagonists & inhibitors , Animals , Anticholesteremic Agents/chemistry , Antioxidants/chemistry , In Vitro Techniques , Indicators and Reagents , Indoles/chemistry , Intestinal Absorption , Lipids/chemistry , Male , Rats , Rats, Wistar , Solubility , Structure-Activity Relationship , Water
SELECTION OF CITATIONS
SEARCH DETAIL